CN117916365B - 用于治疗结晶样视网膜变性的重组腺相关病毒载体 - Google Patents

用于治疗结晶样视网膜变性的重组腺相关病毒载体 Download PDF

Info

Publication number
CN117916365B
CN117916365B CN202280050016.6A CN202280050016A CN117916365B CN 117916365 B CN117916365 B CN 117916365B CN 202280050016 A CN202280050016 A CN 202280050016A CN 117916365 B CN117916365 B CN 117916365B
Authority
CN
China
Prior art keywords
nucleic acid
acid molecule
cyp4v2
isolated nucleic
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202280050016.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN117916365A (zh
Inventor
郭璐
陶冶铮
田幸雪
曲彬
李伟
朱晰
赵小平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Tianze Yuntai Biopharmaceutical Co Ltd
Original Assignee
Shanghai Tianze Yuntai Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Tianze Yuntai Biomedical Co ltd filed Critical Shanghai Tianze Yuntai Biomedical Co ltd
Publication of CN117916365A publication Critical patent/CN117916365A/zh
Application granted granted Critical
Publication of CN117916365B publication Critical patent/CN117916365B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/415—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
    • C12Y114/14001—Unspecific monooxygenase (1.14.14.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280050016.6A 2021-07-15 2022-07-15 用于治疗结晶样视网膜变性的重组腺相关病毒载体 Active CN117916365B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021106619 2021-07-15
CNPCT/CN2021/106619 2021-07-15
PCT/CN2022/106089 WO2023284873A1 (en) 2021-07-15 2022-07-15 Recombinant adeno-associated viral vectors for treating bietti crystalline dystrophy

Publications (2)

Publication Number Publication Date
CN117916365A CN117916365A (zh) 2024-04-19
CN117916365B true CN117916365B (zh) 2025-03-14

Family

ID=84919061

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280050016.6A Active CN117916365B (zh) 2021-07-15 2022-07-15 用于治疗结晶样视网膜变性的重组腺相关病毒载体

Country Status (5)

Country Link
US (1) US12371474B2 (https=)
EP (1) EP4370663A4 (https=)
JP (2) JP2024524707A (https=)
CN (1) CN117916365B (https=)
WO (1) WO2023284873A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12590320B2 (en) 2017-07-31 2026-03-31 Reflection Biotechnologies Limited Cellular models of and therapies for ocular diseases

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114381465B (zh) * 2021-12-22 2024-01-16 苏州诺洁贝生物技术有限公司 优化的cyp4v2基因及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111630170A (zh) * 2017-07-31 2020-09-04 映像生物有限公司 眼部疾病的细胞模型及用于眼部疾病的疗法
CN114381465A (zh) * 2021-12-22 2022-04-22 苏州诺洁贝生物技术有限公司 优化的cpy4v2基因及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CN109136266B (zh) * 2018-08-10 2022-02-18 深圳泓熙生物科技发展有限公司 用于治疗或预防结晶样视网膜色素变性的基因载体及其用途
KR20220022107A (ko) * 2018-12-05 2022-02-24 아베오나 테라퓨틱스 인코퍼레이티드 유전자 전달을 위한 재조합 아데노-연관 바이러스 벡터
US20220154211A1 (en) * 2019-02-25 2022-05-19 Novartis Ag Compositions and methods to treat bietti crystalline dystrophy
SG11202108044YA (en) * 2019-02-25 2021-09-29 Novartis Ag Compositions and methods to treat bietti crystalline dystrophy
CN113106124B (zh) * 2020-06-09 2022-09-23 北京中因科技有限公司 表达cyp4v2的aav载体及其用途
CN111733174B (zh) * 2020-08-07 2021-02-09 北京大学第三医院（北京大学第三临床医学院） 一种分离的核酸分子及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111630170A (zh) * 2017-07-31 2020-09-04 映像生物有限公司 眼部疾病的细胞模型及用于眼部疾病的疗法
CN114381465A (zh) * 2021-12-22 2022-04-22 苏州诺洁贝生物技术有限公司 优化的cpy4v2基因及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AAV2-mediated gene therapy for Bietti crystalline dystrophy provides functional CYP4V2 in multiple relevant cell models;Wang J 等;《Sci Rep》;20220609;第12卷(第1期);第1-13页 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12590320B2 (en) 2017-07-31 2026-03-31 Reflection Biotechnologies Limited Cellular models of and therapies for ocular diseases

Also Published As

Publication number Publication date
JP7811415B2 (ja) 2026-02-05
CN117916365A (zh) 2024-04-19
US12371474B2 (en) 2025-07-29
JP2025090820A (ja) 2025-06-17
EP4370663A4 (en) 2025-03-26
EP4370663A1 (en) 2024-05-22
WO2023284873A1 (en) 2023-01-19
JP2024524707A (ja) 2024-07-05
US20240309068A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
US20220331409A1 (en) Factor ix gene therapy
US20250236887A1 (en) Adeno-associated virus (aav) systems for treatment of genetic hearing loss
EP3717636B1 (en) Adeno-associated virus variant capsids and use for inhibiting angiogenesis
EP3445773B1 (en) Adeno-associated virus variant capsids and methods of use thereof
CA3125770A1 (en) Methods and systems for producing aav particles
US20220154211A1 (en) Compositions and methods to treat bietti crystalline dystrophy
HK1249548A1 (zh) 用於无脉络膜的基因疗法的aav载体
JP7811415B2 (ja) ビエッティ結晶性ジストロフィー治療のための遺伝子組換アデノ随伴ウイルスベクター
JP2025069281A (ja) 調節可能な発現系
US20240318199A1 (en) Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders
JP2025539750A (ja) 前頭側頭型認知症の遺伝子治療
JP2019505238A (ja) 網膜錐体細胞の疾患を治療するための遺伝子治療
JP2023526449A (ja) パーキンソン病を治療するための、増加した活性を有するパーキン変異体の遺伝子治療送達
HK40112621B (zh) 用於治疗结晶样视网膜变性的重组腺相关病毒载体
HK40112621A (zh) 用於治疗结晶样视网膜变性的重组腺相关病毒载体
WO2025162449A1 (en) Compositions and methods for the treatment of heart disease
TW202434733A (zh) 重組腺相關病毒載體
JP2026509301A (ja) 遺伝子治療

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40112621

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 201210 Shanghai Pudong New Area Galileo Road No. 11 Building 2

Patentee after: Shanghai Tianze Yuntai Biopharmaceutical Co., Ltd.

Country or region after: China

Address before: No.66210, 3rd floor, Pudong Free Trade Zone, Shanghai, China

Patentee before: Shanghai Tianze Yuntai biomedical Co.,Ltd.

Country or region before: China

CP03 Change of name, title or address